🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the effort against superbug strains of the infection, according to scientists.

An International Public Health Issue

Gonorrhoea infections are escalating around the world, with figures suggesting over 82 million new cases annually. Particularly high rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the drug firm its industry partner to develop it.

“This approval marks a significant shift in the management of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Data and Global Access

According to data detailed in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the typical regimen, which uses a dual-drug approach. The trial enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Clinicians directly involved have shared optimism. Having a one-pill regimen like this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.